Stay updated with breaking news from Repligen Daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Repligen (NASDAQ:RGEN – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided EPS guidance of 1.420-1.490 for the period, compared to the consensus EPS estimate of 1.770. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $660.7 million. Repligen […]
Repligen (NASDAQ:RGEN – Get Free Report) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 1.420-1.490 for the period, compared to the consensus estimate of 1.770. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $660.7 million. Repligen also updated […]
Repligen (NASDAQ:RGEN – Free Report) had its target price lifted by KeyCorp from $210.00 to $220.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has an overweight rating on the biotechnology company’s stock. RGEN has been the subject of several other research reports. JPMorgan Chase & Co. upped their price target on […]
Headlands Technologies LLC purchased a new stake in Repligen Co. (NASDAQ:RGEN – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 474 shares of the biotechnology company’s stock, valued at approximately $75,000. Several other institutional investors have also recently added to […]
Headlands Technologies LLC purchased a new stake in Repligen Co. (NASDAQ:RGEN – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 474 shares of the biotechnology company’s stock, valued at approximately $75,000. Several other institutional investors have also recently added to […]